Minireviews
Copyright ©The Author(s) 2015.
World J Hepatol. Apr 28, 2015; 7(6): 885-895
Published online Apr 28, 2015. doi: 10.4254/wjh.v7.i6.885
Table 1 Results from trials: Interferon-ribavirin combined treatments in patients with end-stage renal disease and hepatitis C virus ınfection
Ref.YearNo. of patientsProportion with HCV genotype 1 (%)TreatmentSVR (%)Dropout (%)
Tan et al[85]20015NAIFN-3.0 MU/d to 3 times/wk + RBV 200 mg/d, 3 times/wk for 40 wkNA40
Mousa et al[86]20042060-66IFN-3.0 MU/d to 3 times/wk + RBV 200 mg/d, 3 times/wk
For 24 wk660
For 48 wk550
Bruchfeld et al[87]2006666PegIFN - 50 μg/wk + RBV 200-400 mg/d for 24-48 wk (depending on genotype)5050
Rendina et al[88]20073545.7PegIFN-α2a 135 μg/wk + RBV 200 mg/d for 24-48 wk (depending on genotype)9715